ArticleJournal of assisted reproduction and genetics2026
Restoration of spermatogenesis in a male with prolactinoma-induced hypogonadotropic hypogonadism using follitropin delta and recombinant choriogonadotropin alfa: a case report.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollitropin delta is a recombinant human follicle-stimulating hormone (FSH) produced in the human PER.C6 cell line, approved exclusively for controlled ovarian stimulation in women. Its unique glycosylation profile confers distinct pharmacokinetic advantages over Chinese hamster ovary-derived follitropin alfa. To date, no published report exists on the use of follitropin delta in males. The present case describes the first successful off-label use of follitropin delta in combination with recombinant choriogonadotropin alfa (hCG) to restore spermatogenesis in a male patient with prolactinoma-induced hypogonadotropic hypogonadism and exogenous testosterone-associated azoospermia. CASE REPORT: A 30-year-old male with a 6-cm pituitary prolactinoma diagnosed at age 18, managed with cabergoline, presented with azoospermia following 2 years of testosterone undecanoate replacement therapy. There was confirmed suppression of gonadotropins (luteinizing hormone 0.3 mIU/mL and FSH 0.3 mIU/mL) and prolactin of 100 ng/mL. Hormonal stimulation was initiated with follitropin delta 10 µg twice weekly and hCG alfa (~ 125 µg every 4-5 days), alongside continued cabergoline. After 4 months of therapy, semen analysis revealed sperm concentration of 3.5 million/mL (total sperm count 4.9 million/ejaculate). Testosterone levels normalized, with marked clinical improvement.
conclusionThis case provides the first evidence that follitropin delta can successfully replace conventional FSH preparations in male gonadotropin stimulation protocols. Spermatogenesis was restored within a favorable timeframe, enabling access to assisted reproductive technology (IVF/ICSI). Nevertheless, these findings are limited to a single case report and require confirmation in larger studies.
Indexed as
Identifiers
42533173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.